Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?
- 15 March 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (6), 959-962
- https://doi.org/10.1200/jco.2003.11.071
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind TrialJournal of Clinical Oncology, 2000
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1996
- Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.Journal of Clinical Oncology, 1995
- Long-term survival of patients treated with combination chemotherapy for metastatic breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991